13 October 2022  
EMA/815806/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Brukinsa 
zanubrutinib 
On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Brukinsa. The marketing authorisation holder for this medicinal product is BeiGene Ireland Ltd. 
The CHMP adopted a new indication for Brukinsa to include the treatment of chronic lymphocytic 
leukaemia. 
For information, the full indications for Brukinsa will be as follows:2 
Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s 
macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment 
for patients unsuitable for chemo-immunotherapy. 
Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic 
lymphocytic leukaemia (CLL). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
